Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma

J Clin Exp Hematop. 2019;59(2):98-100. doi: 10.3960/jslrt.19006.

Authors

Dai Maruyama¹, Hirokazu Nagai², Noriko Fukuhara³, Toshiyuki Kitano⁴, Takayuki Ishikawa⁵, Tomoaki Nishikawa⁶

Affiliations

¹ Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
² Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
³ Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
⁴ Department of Hematology and Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
⁵ Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
⁶ Janssen Pharmaceutical K.K., Tokyo, Japan.

No abstract available

Keywords: Japanese patients; covalent BTK inhibitor; ibrutinib; mantle cell lymphoma; phase II clinical trial.

Publication types

Clinical Trial, Phase II
Letter

MeSH terms

Adenine / analogs & derivatives
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Drug Resistance, Neoplasm
Humans
Japan
Lymphoma, Mantle-Cell / drug therapy*
Lymphoma, Mantle-Cell / mortality
Lymphoma, Mantle-Cell / pathology*
Molecular Targeted Therapy
Piperidines
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use*
Pyrazoles / administration & dosage
Pyrazoles / adverse effects
Pyrazoles / therapeutic use*
Pyrimidines / administration & dosage
Pyrimidines / adverse effects
Pyrimidines / therapeutic use*
Recurrence
Retreatment
Treatment Outcome

Substances

Antineoplastic Agents
Piperidines
Protein Kinase Inhibitors
Pyrazoles
Pyrimidines
ibrutinib
Adenine